Home Other Building Blocks 123524-52-7
123524-52-7,MFCD00865803
Catalog No.:AA000KNH

123524-52-7 | Azelnidipine

Pack Size
Purity
Availability
Price(USD)
Quantity
  
25mg
97%
in stock  
$6.00   $4.00
- +
50mg
97%
in stock  
$8.00   $6.00
- +
100mg
97%
in stock  
$11.00   $8.00
- +
1g
98%(HPLC)
in stock  
$80.00   $56.00
- +
5g
98%(HPLC)
in stock  
$239.00   $167.00
- +
  • Technical Information
  • Properties
  • Upstream Synthesis Route
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Upstream Synthesis Route
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA000KNH
Chemical Name:
Azelnidipine
CAS Number:
123524-52-7
Molecular Formula:
C33H34N4O6
Molecular Weight:
582.6463
MDL Number:
MFCD00865803
SMILES:
CC(OC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1)N)C
Properties
Computed Properties
 
Complexity:
1080  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
43  
Hydrogen Bond Acceptor Count:
9  
Hydrogen Bond Donor Count:
2  
Rotatable Bond Count:
10  
Undefined Atom Stereocenter Count:
1  
XLogP3:
6  

Upstream Synthesis Route

[1]Patent:CN103183663,2017,B,.Locationinpatent:Paragraph0032;0034

[2]ChemicalandPharmaceuticalBulletin,1995,vol.43,#5,p.797-817

[3]Patent:EP1577309,2005,A1,.Locationinpatent:Page/Pagecolumn4

[1]Patent:CN105461691,2016,A,.Locationinpatent:Paragraph0017-0018

[1]ChemicalandPharmaceuticalBulletin,1995,vol.43,#5,p.797-817

[1]Patent:CN105461691,2016,A,

[1]Patent:CN105461691,2016,A,

Downstream Synthesis Route
39562-25-9   
1-benzhydrylazetidin-3-yl3-amino-3-iminopropanoateacetate 
  123524-52-7 

[1]Patent:CN103183663,2017,B.Locationinpatent:Paragraph0032;0034

[2]ChemicalandPharmaceuticalBulletin,1995,vol.43,p.797-817

[3]Patent:EP1577309,2005,A1.Locationinpatent:Page/Pagecolumn4

[1]ChemicalandPharmaceuticalBulletin,1995,vol.43,p.797-817

[1]Patent:EP1577309,2005,A1.Locationinpatent:Page/Pagecolumn4-5

104-15-4    123524-52-7   
Azelnidipinetosylate 

[1]Patent:EP1961749,2008,A1.Locationinpatent:Page/Pagecolumn10

Literature

Title: Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor.

Journal: Scientific reports 20140101

Title: Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.

Journal: The Tohoku journal of experimental medicine 20121201

Title: Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.

Journal: The American journal of medicine 20121001

Title: The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.

Journal: Diabetes & vascular disease research 20121001

Title: Association of changes in ambulatory arterial stiffness index and pulse wave velocity during antihypertensive treatment: the J-CORE study.

Journal: American journal of hypertension 20120801

Title: Azelnidipine, unique calcium channel blocker could prevent stress-induced cardiac dysfunction like α·β blocker.

Journal: Journal of cardiology 20120701

Title: Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.

Journal: Hypertension (Dallas, Tex. : 1979) 20120601

Title: Calcium antagonist added to angiotensin receptor blocker: a recipe for reducing blood pressure variability?: evidence from day-by-day home blood pressure monitoring.

Journal: Hypertension (Dallas, Tex. : 1979) 20120601

Title: Mechanistic study on degradation of azelnidipine solution under radical initiator-based oxidative conditions.

Journal: Journal of pharmaceutical and biomedical analysis 20120305

Title: Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension 20120301

Title: Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence.

Journal: British journal of pharmacology 20120201

Title: Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.

Journal: Bioorganic & medicinal chemistry letters 20120115

Title: Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.

Journal: Journal of nephrology 20120101

Title: Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats.

Journal: Clinical and experimental hypertension (New York, N.Y. : 1993) 20120101

Title: Long-term effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney disease: a randomized controlled study.

Journal: American journal of nephrology 20120101

Title: Solid state characterizations and analysis of stability in azelnidipine polymorphs.

Journal: Chemical & pharmaceutical bulletin 20120101

Title: Azelnidipine inhibits Msx2-dependent osteogenic differentiation and matrix mineralization of vascular smooth muscle cells.

Journal: International heart journal 20120101

Title: Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria.

Journal: Cardiovascular drugs and therapy 20110801

Title: Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension 20110801

Title: L-/T-type Ca channel blockers for kidney protection: ready for sophisticated use of Ca channel blockers.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension 20110801

Title: Azelnidipine, a new calcium channel blocker, promotes skin wound healing in diabetic rats.

Journal: The Journal of surgical research 20110701

Title: Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease.

Journal: Clinical cardiology 20110601

Title: Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker.

Journal: American journal of hypertension 20110401

Title: Reduction of albuminuria with antihypertensive treatment: is more always better?

Journal: American journal of hypertension 20110401

Title: Association between aldosterone induced by antihypertensive medication and arterial stiffness reduction: the J-CORE study.

Journal: Atherosclerosis 20110301

Title: Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property.

Journal: International journal of cardiology 20110121

Title: Comparison of combination therapy of olmesartan plus azelnidipine or hydrochlorothiazide on renal and vascular damage in SHR/NDmcr-cp rats.

Journal: Kidney & blood pressure research 20110101

Title: Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J).

Journal: Circulation journal : official journal of the Japanese Circulation Society 20110101

Title: Comparative effects of azelnidipine and amlodipine on myocardial function and mortality after ischemia/reperfusion in dogs.

Journal: Journal of pharmacological sciences 20110101

Title: Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study.

Journal: Vascular health and risk management 20110101

Title: Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function--a crossover trial (AGENT).

Journal: Cardiovascular diabetology 20110101

Title: Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis.

Journal: Cardiovascular diabetology 20110101

Title: Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.

Journal: Bioorganic & medicinal chemistry 20101115

Title: Azelnidipine-induced chyloperitoneum in a patient with microscopic polyangiitis.

Journal: Clinical and experimental nephrology 20101001

Title: Combination therapy of calcium channel blocker and angiotensin II receptor blocker reduces augmentation index in hypertensive patients.

Journal: The American journal of the medical sciences 20100501

Title: Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.

Journal: Clinical therapeutics 20100501

Title: Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice.

Journal: Circulation journal : official journal of the Japanese Circulation Society 20100401

Title: Cardiovascular effects of azelnidipine in comparison with those of amlodipine assessed in the halothane-anaesthetized dog.

Journal: Basic & clinical pharmacology & toxicology 20100201

Title: [Enantiomeric separation of azelnidipine by high performance liquid chromatography with chiral stationary phase].

Journal: Se pu = Chinese journal of chromatography 20100201

Title: Azelnidipine, a long-acting calcium channel blocker, could control hypertension without decreasing cerebral blood flow in post-ischemic stroke patients. A 123I-IMP SPECT follow-up study.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension 20100101

Title: [Calcium antagonists: current and future applications based on new evidence. Calcium channel blockers and autonomic nervous system].

Journal: Clinical calcium 20100101

Title: Beneficial effect of combination therapy comprising angiotensin II receptor blocker plus calcium channel blocker on plasma adiponectin levels.

Journal: Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101

Title: Plasma renin activity and aldosterone concentration are not altered by the novel calcium channel antagonist, azelnidipine, in hypertensive patients.

Journal: Internal medicine (Tokyo, Japan) 20100101

Title: Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker.

Journal: Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101

Title: Cytokine reducing effect of azelnidipine in human peripheral blood mononuclear cells.

Journal: Biological & pharmaceutical bulletin 20100101

Title: Azelnidipine and amlodipine: a comparison of their effects and safety in a randomized double-blinded clinical trial in Chinese essential hypertensive patients.

Journal: Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101

Title: Azelnidipine protects myocardium in hyperglycemia-induced cardiac damage.

Journal: Cardiovascular diabetology 20100101

Title: Azelnidipine exerts renoprotective effects by improvement of renal microcirculation in angiotensin II infusion rats.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20091201

Title: A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension 20091201

Title: Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension 20091101

Title: Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.

Journal: Hypertension (Dallas, Tex. : 1979) 20091001

Title: Central blood pressure under angiotensin and calcium channel blockade.

Journal: Hypertension (Dallas, Tex. : 1979) 20091001

Title: Impact of azelnidipine treatment on left ventricular diastolic performance in patients with hypertension and mild diastolic dysfunction: multi-center study with echocardiography.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension 20091001

Title: Combination of chronic exercise and antihypertensive therapy enhances renoprotective effects in rats with renal ablation.

Journal: American journal of hypertension 20091001

Title: Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo university (ALPS-J).

Journal: Cardiovascular drugs and therapy 20091001

Title: Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats.

Journal: Journal of hypertension 20090901

Title: Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers.

Journal: Journal of cardiovascular pharmacology 20090701

Title: Combination use of immune complexes and a Ca2(+) channel blocker azelnidipine enhances interleukin-12 p40 secretion without T helper type 17 cytokine secretion in human monocyte-derived dendritic cells.

Journal: Clinical and experimental immunology 20090601

Title: Therapeutic strategy for ischemic stroke.

Journal: Neurochemical research 20090401

Title: Chronotropic effects of azelnidipine, a slow- and long-acting dihydropyridine-type calcium channel blocker, in anesthetized dogs: a comparison with amlodipine.

Journal: Journal of cardiovascular pharmacology 20090401

Title: Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R.

Journal: European journal of pharmacology 20090301

Title: Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists.

Journal: American journal of hypertension 20090201

Title: Comparative effects of olmesartan and azelnidipine on atrial structural remodeling in spontaneously hypertensive rats.

Journal: Pharmacology 20090101

Title: Gene and stem cell therapy in ischemic stroke.

Journal: Cell transplantation 20090101

Title: Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis.

Journal: Drug metabolism and pharmacokinetics 20090101

Title: Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys.

Journal: Kidney & blood pressure research 20090101

Title: Azelnidipine decreases plasma matrix metalloproteinase-9 levels after endovascular abdominal aortic aneurysm repair.

Journal: The Kurume medical journal 20090101

Title: Enhanced pulsatile pressure accelerates vascular smooth muscle migration: implications for atherogenesis of hypertension.

Journal: Cardiovascular research 20081201

Title: Renoprotective effect of azelnidipine in rats.

Journal: Biological & pharmaceutical bulletin 20081201

Title: Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.

Journal: Journal of cardiovascular pharmacology 20081201

Title: Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension 20081201

Title: Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.

Journal: Clinical nephrology 20081101

Title: Determination of azelnidipine by LC-ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers.

Journal: Die Pharmazie 20080801

Title: In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension 20080801

Title: In vivo imaging of renal redox status during azelnidipine treatment.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension 20080801

Title: Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension 20080601

Title: Effects of azelnidipine on the autonomic functions and its influence on arterial stiffness and endothelial functions.

Journal: Journal of cardiology 20080401

Title: Spectroscopic studies on the interaction of azelnidipine with bovine serum albumin.

Journal: International journal of pharmaceutics 20080303

Title: Effects of antihypertensive drugs and exercise training on insulin sensitivity in spontaneously hypertensive rats.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension 20080301

Title: Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice.

Journal: Atherosclerosis 20080101

Title: Calcium channel blocker, azelnidipine, reduces lipid hydroperoxides in patients with type 2 diabetes independent of blood pressure.

Journal: Endocrine journal 20071201

Title: Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats.

Journal: Brain research 20071024

Title: Antioxidative effects of azelnidipine on mesangial cell proliferation induced by highly concentrated insulin.

Journal: European journal of pharmacology 20070719

Title: Enantioselective determination of azelnidipine in human plasma using liquid chromatography-tandem mass spectrometry.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070601

Title: Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.

Journal: The American journal of the medical sciences 20070601

Title: Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure.

Journal: Journal of cardiovascular pharmacology 20070601

Title: Effect of benidipine on simvastatin metabolism in human liver microsomes.

Journal: Drug metabolism and pharmacokinetics 20070601

Title: The long-acting Ca2+-channel blocker azelnidipine prevents left ventricular remodeling after myocardial infarction.

Journal: Journal of pharmacological sciences 20070401

Title: Azelnidipine attenuates cardiovascular and sympathetic responses to air-jet stress in genetically hypertensive rats.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension 20070401

Title: Azelnidipine inhibits H2O2-induced cell death in neonatal rat cardiomyocytes.

Journal: Cardiovascular drugs and therapy 20070201

Title: Determination of azelnidipine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry.

Journal: Journal of pharmaceutical and biomedical analysis 20070117

Title: Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity.

Journal: Clinical and experimental hypertension (New York, N.Y. : 1993) 20070101

Title: Effects of calcium channel blocker azelnidipine on experimental abdominal aortic aneurysms.

Journal: Surgery today 20070101

Title: Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity.

Journal: Arzneimittel-Forschung 20070101

Title: SDF-1-induced adhesion of monocytes to vascular endothelium is modulated by azelnidipine via protein kinase C inhibition.

Journal: European journal of pharmacology 20061215

Title: Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.

Journal: The Journal of pharmacology and experimental therapeutics 20061201

Title: Tilting-induced decrease in systolic blood pressure in bedridden hypertensive elderly inpatients: effects of azelnidipine.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension 20061201

Title: Simultaneous determination of azelnidipine and two metabolites in human plasma using liquid chromatography-tandem mass spectrometry.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20061121

Title: The actions of azelnidipine, a dihydropyridine-derivative Ca antagonist, on voltage-dependent Ba2+ currents in guinea-pig vascular smooth muscle.

Journal: British journal of pharmacology 20061101

Title: The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.

Journal: Journal of hypertension 20061001

Title: Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis.

Journal: Journal of hypertension 20061001

Title: Azelnidipine down-regulates renal angiotensin-converting enzyme and mineralocorticoid receptor mRNA in diabetic hypertensive rats.

Journal: Journal of pharmacological sciences 20061001

Title: Efficacy of azelnidipine on home blood pressure and pulse rate in patients with essential hypertension: comparison with amlodipine.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension 20061001

Title: Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species.

Journal: European journal of pharmacology 20060928

Title: A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent-associated neointimal formation in non-human primates.

Journal: Journal of hypertension 20060901

Title: [Novel actions of calcium channel blockers].

Journal: Nihon rinsho. Japanese journal of clinical medicine 20060801

Title: Effects of calcium channel blockade on angiotensin II-induced peritubular ischemia in rats.

Journal: The Journal of pharmacology and experimental therapeutics 20060301

Title: Comparative effects of azelnidipine and other Ca2+-channel blockers on the induction of inducible nitric oxide synthase in vascular smooth muscle cells.

Journal: Journal of cardiovascular pharmacology 20060201

Title: The newly developed calcium antagonist, azelnidipine, increases drain volume in continuous ambulatory peritoneal dialysis patients.

Journal: Advances in peritoneal dialysis. Conference on Peritoneal Dialysis 20060101

Title: Azelnidipine, a new long-acting calcium-channel blocker, inhibits tumour necrosis factor-alpha-induced monocyte chemoattractant protein-1 expression in endothelial cells.

Journal: The Journal of international medical research 20060101

Title: Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension 20051201

Title: Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.

Journal: Journal of hypertension 20050701

Title: Effect of azelnidipine on angiotensin II-mediated growth-promoting signaling in vascular smooth muscle cells.

Journal: Molecular pharmacology 20050501

Title: Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist.

Journal: Medical hypotheses 20050101

Title: Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (AGE)-injected rats.

Journal: International journal of tissue reactions 20050101

Title: Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells.

Journal: Drugs under experimental and clinical research 20050101

Title: Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension 20041001

Title: Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties.

Journal: Journal of cardiovascular pharmacology 20040501

Title: Biliary excretion of azelnidipine, a calcium antagonist, in rats.

Journal: Journal of gastroenterology and hepatology 20040401

Title: Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.

Journal: Hypertension (Dallas, Tex. : 1979) 20040201

Title: Antioxidant effect of a new calcium antagonist, azelnidipine, in cultured human arterial endothelial cells.

Journal: The Journal of international medical research 20040101

Title: [Pharmacological profiles and clinical effects of azelnidipine, a long-acting calcium channel blocker].

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20031201

Title: Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension 20030301

Title: Azelnidipine. CS 905, Calblock, RS 9054.

Journal: Drugs in R&D 20030101

Title: Azelnidipine.

Journal: Drugs 20030101

Title: Combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and a calcium antagonist: beyond the renoprotective effects of ACE inhibitor monotherapy in a spontaneous hypertensive rat with renal ablation.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension 20020501

Title: Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker.

Journal: Japanese journal of pharmacology 19890901

Title: Komoda H, Inoue T, Node K. Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker. Clin Exp Hypertens. 2010 Jan;32(2):121-8.

Title: Kain V, Kumar S, Sitasawad SL. Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis. Cardiovasc Diabetol. 2011 Nov 4;10:97.

Title: Takano Y, Ueyama T, Ishikura F. Azelnidipine, unique calcium channel blocker could prevent stress-induced cardiac dysfunction like α·β blocker. J Cardiol. 2012 Jul;60(1):18-22.

Title: Shimizu T, Tanaka T, Iso T et al. Azelnidipine inhibits MSX2-dependent osteogenic differentiation and matrix mineralization of vascular smooth muscle cells. Int Heart J. 2012;53(5):331-5.

Title: Ohyama T, Sato K, Kishimoto K et al. Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence. Br J Pharmacol. 2012 Feb;165(4b):1173-87.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:123524-52-7 Molecular Formula|123524-52-7 MDL|123524-52-7 SMILES|123524-52-7 Azelnidipine